Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Hepatology|March 1, 2011
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patientsEdward J Gane, Regine Rouzier, Catherine Stedman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 29, 2005
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infectionThomas B Campbell, Nancy S Shulman, Steven C Johnson, et al.
The Journal of Infectious Diseases|March 24, 2009
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patientsSeverine Margeridon-Thermet, Nancy S Shulman, Aijaz Ahmed, et al.
Gastroenterology|March 16, 2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePaul J Pockros, K Rajender Reddy, Parvez S Mantry, et al.
Kidney International Reports|February 19, 2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseEric Lawitz, Edward Gane, Eric Cohen, et al.
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.
Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.
Antimicrobial Agents and Chemotherapy|December 4, 2013
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null respondersEdward J Gane, Régine Rouzier, Alicja Wiercinska-Drapalo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.
Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.
Pageof 3